SCHEMBL4673475

SCHEMBL4673475

O=C(C=C(O)c1nc[nH]n1)c1ccc(Oc2ccccc2C(F)(F)F)o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.34
PPARG P37231 1/20 0.33
NFE2L2 Q16236 1/20 0.33
FAAH O00519 2/20 0.33
BCHE P06276 2/20 0.33
ACHE P22303 2/20 0.33
LPAR1 Q92633 1/20 0.32
LPAR5 Q9H1C0 1/20 0.32
MCL1 Q07820 1/20 0.32
LMNA P02545 3/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NOTUM Q6P988 1/20 0.32
MAOB P27338 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672776 0.85 ALDH1A1 (0.38) RXRABCHELPAR1LPAR5LMNA
SCHEMBL4675045 0.85 HPGD (0.34) RXRARXRBLMNAALDH1A1KDM4E
SCHEMBL4679125 0.84 MRGPRX4 (0.37) RXRARXRBRXRGMRGPRX4NFE2L2
SCHEMBL4676006 0.83 NPSR1 (0.37) FAAHALDH1A1POLBSMN1; SMN2
SCHEMBL4671462 0.82 MRGPRX4 (0.35) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL4675135 0.82 LTA4H (0.35) PPARGFAAHALDH1A1MAOBSMN1; SMN2
SCHEMBL4672746 0.81 PTPN11 (0.45) RXRARXRBRXRGLMNAALDH1A1
SCHEMBL4678496 0.80 KDM4E (0.39) MRGPRX4PPARGALDH1A1KDM4EMAOB
SCHEMBL4678744 0.80 ALOX5 (0.39) LMNAALDH1A1
SCHEMBL4675422 0.80 RXRA (0.33) RXRARXRBRXRGMRGPRX4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 RXRA 1268/4885RXRB 1235/4885RXRG 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.